NDRG4 Gene Methylation in Blood Leukocytes and Gastric Cancer Risk

310 gastric cancer patients and 300 controls were analyzed in a two-phase case-control study to investigate the association between NDRG4 gene methylation in peripheral blood leukocytes and gastric cancer risk, chemotherapy efficacy, and prognosis. The dataset, authored by Zhan Li and last updated on 2026-04-27, includes results from bioinformatics analyses of TCGA and GEO databases and methylation comparisons across rs7202037 SNP genotypes. The file is a 19.0 KB DOCX document.

Use Cases

• Assessing gastric cancer risk based on methylation levels at specific NDRG4 CpG sites (chr16:58497239, chr16:58497262).
• Predicting chemotherapy efficacy in gastric cancer patients using NDRG4 methylation status.
• Analyzing the association between NDRG4 gene methylation and patient progression-free survival (PFS).
• Investigating the relationship between the rs7202037 SNP genotype and NDRG4 methylation levels.

Strengths

• Includes data from 610 total participants (310 patients, 300 controls).
• Reports specific odds ratios and confidence intervals for two CpG sites associated with cancer risk.
• Links methylation data to clinical outcomes like chemotherapy efficacy and progression-free survival.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The dataset is very small (19.0 KB), suggesting limited scope, likely containing summary results rather than raw data.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

Analysis utilizes data from TCGA and GEO databases, supplemented by a two-phase case-control study.

Collection Method

Bioinformatics analysis and a two-phase case-control study investigating methylation via specific CpG sites and SNP genotyping.

Freshness

Last updated 2026-04-27 04:12:25; freshness should be verified.